Lupin Unveils Strategic Partnership Program to Expand Reach of
its Long-Acting Injectable Platform.
Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi’s Long-Acting Injectable Platform
Nanomi Receives CMO Award for Life Science Leadership in Drug Delivery
